Leqembi® annual sales exceed EUR 500 million – second sales milestone achieved

BioArctic will receive a EUR 20 million milestone payment after partner Eisai reported Leqembi global sales surpassed EUR 500 million in fiscal 2025. The update is positive for BioArctic’s collaboration revenue stream and confirms continued commercial traction for the Alzheimer’s drug. The news is financially meaningful but likely limited in market-moving impact.

Analysis

This is incremental proof that the Alzheimer’s franchise is moving from promise to monetization, which matters more for BioArctic’s valuation than the headline euro amount. The key second-order effect is not the cash itself, but validation that the asset is crossing the threshold where milestone economics can start offsetting development risk and fund the pipeline without more dilution. That shifts BioArctic from a binary R&D story toward a royalty-plus-milestone annuity profile over the next 12-24 months.

For Eisai, the signal is that commercial momentum is still intact despite the normal post-launch friction of access, infusion logistics, and physician caution around safety monitoring. The next inflection is whether sales growth can remain steep enough to trigger additional payments repeatedly; if the pace stalls, this becomes a one-time confidence boost rather than a durable earnings lever. Competitively, a strengthening Leqembi trajectory raises pressure on other anti-amyloid programs by tightening the window for differentiation on efficacy, convenience, or safety.

The contrarian risk is that the market may overestimate how much of this translates into near-term equity upside for BioArctic. Milestone receipts are lumpy and often discounted once investors see a pattern of “good but not transformative” payments, so the stock can fade if there is no explicit guidance on future milestones or pipeline readthrough. The more durable catalyst is not this payment, but evidence that sales acceleration continues into the next reporting cycle, because that would re-rate the probability of recurring milestone capture and future royalties.

On the downside, any slower uptake from reimbursement scrutiny, infusion capacity constraints, or competitive safety perception could interrupt the sales glidepath within quarters, not years. On the upside, sustained growth would create a feedback loop: more commercial confidence, better partner economics, and improved bargaining power for BioArctic’s broader platform assets.

Key Decisions for Investors

• Long BIOA B on pullbacks over the next 1-2 weeks; treat as a catalyst-driven trade with upside if the market starts capitalizing future milestones, but cut if management provides no evidence of sustained sales acceleration.
• Pair trade: long BIOA B / short a basket of smaller pre-revenue CNS biotech names over 1-3 months; BIOA now has a de-risked cash-flowing partner asset, while the shorts remain dependent on binary clinical readouts.
• If accessible via options, buy 2-3 month calls on Eisai-related exposure only if implied vol is still muted; the asymmetry is that continued Leqembi growth would support multiple milestone events, but the trade should be sized for a modest re-rating rather than a step-change.
• Avoid chasing after the first pop; better entry is on any fade once the market realizes EUR 20M is supportive but not game-changing for intrinsic value.
• Set a catalyst watch for the next Eisai sales update over the next quarter; if growth decelerates materially, rotate out because the market will likely compress milestone expectations quickly.